Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
Trial ID or NCT#
NCT03050463
Status
NOT RECRUITING
Purpose
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.
Official Title
Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Inclusion Criteria:
- Women Diagnosed with breast cancer
- * Female* Age 18 or older* Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI's clinical judgement)* Agree to taking saliva samples and having fMRI scan* No contraindications to MRI imaging (like ferromagnetic metal in their body)* Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments* US Citizen or resident able to receive payment legally* Documented stage 0-III breast cancer* Unilateral breast tumors
- Controls
- * Female* Age 18 or older* Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI's clinical judgement)* Agree to having saliva samples and fMRI scan* No contraindications to MRI imaging (like ferromagnetic metal in their body)* Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments* US Citizen or resident able to receive payment legally
Exclusion Criteria:
- Women Diagnosed with breast cancer
- * Other active cancers within the past 10 years other than squamous cell carcinoma of the skin* Pregnant* Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury* Hearing impaired* Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence* Current use of psychotropic (based on PI's clinical judgement) medication 5 or more days a week
- Controls
- * Cancer diagnosis, current or past* Pregnant* Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury* Hearing impaired* Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence* Current use of psychotropic (based on PI's clinical judgement) medication 5 or more days a week* Breast cancer diagnosis in 1 first degree relative or 2 or more second degree relatives* Ovarian cancer diagnosis in 1 first or second degree relative
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Bita Nouriani
650-723-8479
View on